Category:

Health

Latest

Positive news on Oxford/AstraZeneca COVID-19 vaccine could come Thursday:report

AstraZeneca’s experimental vaccine is probably the world’s leading candidate and most advanced in terms of development, the World Health Organization’s chief scientist said in June.

The company has signed agreements with governments around the globe to supply the vaccine should it be cleared for use.

read more

India’s COVID-19 tally crosses 9 lakh with 28,498 fresh cases; death toll climbs to 23,727

The march of coronavirus infection in the country has picked up pace with the number of cases increasing by more than 26,000 for the fifth consecutive day. It took 110 days for the COVID-19 cases in the country to reach one lakh and just 56 days more to go past the nine-lakh mark.
Around 63.02 per cent of patients have recovered so far.

read more

Human clinical trials for Covid-19 vaccine initiated in India:ICMR

The Drugs Controller General of India (DCGI) has permitted two vaccines — one developed by Bharat Biotech International Limited in collaboration with the Indian Council of Medical Research and another one by ZydasCadila Healthcare Ltd to go in for the first and second phase of human clinical trials.

There are two Indian vaccine candidates that have undergone successful toxicity studies in rats, mice and rabbits and these data was submitted to the DCGI, following which both got clearance to start an early phase human trials earlier this month, Bhargava said at a press briefing.

read more

Network Hospitals have to provide cashless facility to policyholders:IRDAI 

,it is clarified that the policyholders are entitled to cashless facility at all such network providers (hospital) with whom the Insurance company/TPA has entered into an agreement in accordance to the norms of SLA.
In the event of denial of cashless facility at any such enlisted network providers (hospitals) the aggrieved policyholders may send a complaint to the concerned insurance company.

read more

Glenmark cuts price of COVID-19 drug favipiravir version to $1 per tablet

Glenmark last month received Indian regulatory approval to make and sell anti-flu drug favipiravir, which is manufactured under the brand name Avigan by a unit of Japan’s Fujifilm Holdings Corp.

Glenmark had priced FabiFlu at 103 rupees per tablet earlier, making it one of the cheapest COVID-19 treatment available in the country.

“Glenmark’s price reduction aims to make FabiFlu further accessible for COVID-19 patients across the country,” the company said in a statement

read more